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Background-—Ivabradine is a heart rate–lowering agent approved to reduce the risk of hospitalization for worsening heart failure.
This study assessed the cost-effectiveness of adding ivabradine to background therapy in the United States from the perspective of
a commercial or Medicare Advantage payer.
Methods and Results-—A cost-effectiveness, cohort-based Markov model using a state transition approach tracked a cohort of
heart failure patients with heart rate ≥70 beats per minute in sinus rhythm who were treated with ivabradine+background therapy
or background therapy alone. Model inputs, including adjusted hazard ratios, rates of hospitalization and mortality, adverse events,
and utility-regression equations, were derived from a large US claims database and SHIFT (Systolic Heart failure treatment with the
If inhibitor ivabradine Trial). In the commercial population, ivabradine+background therapy was associated with a cost savings of
$8594 versus the cost of background therapy alone over a 10-year time horizon, primarily because of reduced hospitalization.
Ivabradine was associated with an incremental beneﬁt of 0.24 quality-adjusted life years over a 10-year time horizon. In the
Medicare Advantage population, the incremental cost-effectiveness ratio for ivabradine was estimated to be $24 920/quality-
adjusted life years.
Conclusions-—The cost-effectiveness model suggests that for a commercial population, the addition of ivabradine to background
therapy was associated with cost savings and improved clinical outcomes. For a Medicare Advantage population, the analysis
indicates that the clinical beneﬁt of ivabradine can be achieved at a reasonable cost. ( J Am Heart Assoc. 2016;5:e003221 doi:
10.1161/JAHA.116.003221)
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H eart failure (HF) is a complex clinical syndromeassociated with a considerable economic burden,
largely because of a high prevalence and a frequent require-
ment for hospitalization.1 In the United States, 5.8 million
people currently suffer from HF, with the prevalence expected
to rise to more than 8 million by 2030.2 About half of patients
with symptomatic HF have reduced ejection fraction.3 The
annual costs of HF are currently estimated at $30.7 billion.2,3
More than two thirds of these costs can be attributed to the
costs associated with hospitalization.4 For Medicare patients,
30-day readmission rates are as high as 25% and HF is the
leading cause of rehospitalization.5
HF is also a condition associated with a poor prognosis,
with 50% of patients dying within 5 years of diagnosis.3 At
particular risk are patients with a high resting heart rate
(HR). HR ≥70 beats per minute (bpm) has been shown to be
a risk marker in HF.6 Patients with a high HR are more likely
to suffer from an exacerbation requiring hospitalization, or to
have cardiovascular death.6,7 Moreover, an analysis of the
prospective, US-based Get With the Guidelines registry
indicated that patients hospitalized for HF with a HR
≥75 bpm at the time of discharge are more likely to be
readmitted within 30 days.7 This result conﬁrms that high HR
is a risk factor for cardiovascular events in HF6 and
highlights the need to regard HR as a target for treatment
in HF.6
Ivabradine (Corlanor; Amgen Inc., Thousand Oaks, CA) is
a hyperpolarization-activated cyclic nucleotide-gated channel
blocker that acts on the sinoatrial node to inhibit the If current
in order to slow HR.8 Ivabradine is indicated for patients
taking the maximally tolerated dose of b-blockers or for those
for whom b-blockers are contraindicated. The most common
side effects (ivabradine versus placebo rates) are bradycardia
From the Evidera, Bethesda, MD (A.R.K., A.T., Y.Z.); Imperial College London,
London, United Kingdom (M.R.C.); Amgen Inc., Thousand Oaks, CA (A.K., N.Y.);
Evidera, Montreal, Quebec, Canada (S.K.).
Accompanying Tables S1 through S6 are available at http://jaha.ahajournals.
org/content/5/5/e003221/DC1/embed/inline-supplementary-material-1.pdf
Correspondence to: Anuraag R. Kansal, PhD, 7101 Wisconsin Ave Ste 1400,
Bethesda, MD 20814. E-mail: anuraag.kansal@evidera.com
Received February 10, 2016; accepted April 9, 2016.
ª 2016 The Authors and Amgen. Published on behalf of the American Heart
Association, Inc., by Wiley Blackwell. This is an open access article under the
terms of the Creative Commons Attribution-NonCommercial License, which
permits use, distribution and reproduction in any medium, provided the
original work is properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.116.003221 Journal of the American Heart Association 1
ORIGINAL RESEARCH
 by guest on May 9, 2016http://jaha.ahajournals.org/Downloaded from 
(10% versus 2.2%), hypertension (8.9% versus 7.8%), atrial
ﬁbrillation (8.3% versus 6.6%), and luminous phenomena
(phosphenes) (2.8% versus 0.5%). Ivabradine was developed
by Les Laboratoires Servier (Paris, France), and it is
distributed and manufactured in the United States by Amgen
Inc.
The addition of ivabradine to background therapy such as
b-blockers, angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, aldosterone antagonists, and diuret-
ics has been investigated in the Systolic Heart failure
treatment with the If inhibitor ivabradine Trial (SHIFT).
9 SHIFT
was a randomized, event-driven trial of ivabradine versus
placebo added to guidelines-driven background therapy in
6558 adult patients with New York Heart Association class II-
IV HF, left ventricular ejection failure ≤35%, and resting heart
rate ≥70 bpm. The primary end point was a composite of time
to cardiovascular death or hospitalization for worsening heart
failure, which was signiﬁcantly reduced with ivabradine+back-
ground therapy (hazard ratio: 0.82, 95% CI: 0.75, 0.90,
P<0.0001). The results of SHIFT also showed that
ivabradine+background therapy reduced hospitalizations for
worsening HF by 26% (relative risk).9 While this indicates that
ivabradine may improve patient outcomes, the economic
implications of adding ivabradine to a standard HF treatment
regimen in the United States have not yet been elucidated.
With the increasing cost of health care in the United
States, there is a growing interest in assessing the cost-
effectiveness of novel treatments.10 When the value of an
intervention is being compared with the best available
alternative, as is the case with ivabradine and background
therapy, an incremental cost-effectiveness ratio (ICER) can be
estimated.10 The aim of this investigation was to develop a
cost-effectiveness model to evaluate the additional value
associated with adding ivabradine to background therapy,
compared with background therapy alone.
Methods
Model Structure
A Markov model taking the perspective of a third-party payer
was used to track a cohort of patients with chronic HF treated
with either ivabradine+background therapy or background
therapy alone over a 10-year time horizon. The study was
designed by Amgen and Evidera; Evidera performed the
analysis under contract to Amgen. The authors of the study
interpreted the data after analysis was complete. US claims
estimates were based on the analyses of the results from the
Optum Research Database between January 1, 2008 and June
30, 2013. SHIFT estimates were based on the analyses of trial
data (with median follow-up of 22.9 months). The model has
the ﬂexibility to take the perspective of a commercial third-
party payer or that of Medicare Advantage. Within this model,
patients with up to 3 cardiovascular hospitalizations were
assigned to 10 mutually exclusive hospitalization states. The
limit of 3 hospitalizations was used to reduce the complexity
of the model. Using a 1-month cycle, patients entered the
model with 0 hospitalizations. With the experience of a
hospitalization event (HF or non-HF cardiovascular), they
would transition to a state with a higher number of
hospitalizations. Patients who did not experience a hospital-
ization remained in the same state. With increasing numbers
of prior HF and non-HF cardiovascular hospitalizations, the
risk of future HF and non-HF cardiovascular hospitalizations
increased, and patient utility decreased. The model consid-
ered costs of treatment, hospitalization, and adverse event
(AE) management. Figure 1 depicts the model structure
through a state-diagram.
Data from US claims, sourced from a large US payer claims
database, were used for both the commercial perspective and
the Medicare Advantage perspective. Many of the inputs for
the model were derived from a post hoc analysis of SHIFT
data. SHIFT was a multinational, randomized, double-blind,
placebo-controlled, parallel-group study involving 6505
patients with symptomatic HF, with a left ventricular ejection
fraction ≤35% and a resting HR ≥70 bpm in sinus rhythm. The
trial was conducted at 677 centers across 37 countries.
Patients were required to have been hospitalized within the
previous year for HF, and to have been receiving stable
background therapy.9 Patients (n=6505) were then randomly
assigned to receive either ivabradine (maximum 7.5 mg twice
daily) or placebo, in addition to background therapy.9 The
median follow-up during the trial was 22.9 months (interquar-
tile range: 18–28 months). Data from this trial, including
treatment efﬁcacy, mortality, drug safety, and utility inputs,
were used within this cost-effectiveness model.
Model Inputs
Drug and clinical inputs
Hospitalization. For the base-case analysis, reference hos-
pitalization rates for background therapy were based on the
analysis of US claims data (Table S1). Hospitalization rates for
patients treated with ivabradine were calculated by adjusting
the reference hospitalization rates using hazard ratios derived
from SHIFT (Table S2). An alternative scenario was also run, in
which hospitalization rates from SHIFT were used as inputs for
the hospitalization rates for patients treated with background
therapy.
Mortality. For both ivabradine and background therapy, HF
and non-HF cardiovascular mortality rates and hazard ratios
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were derived from a post hoc analysis of SHIFT as claims data
do not comprehensively capture mortality (Table S3). Non-
cardiovascular mortality was calculated from the US life
table,11 with cardiovascular-associated mortality excluded.12
The baseline age and sex distribution data used for back-
ground mortality calculation were derived from US claims data
for the reference scenario (ie, percent female: 42.5%; baseline
age: 62.8 years).
Adverse events. Rates of AEs from SHIFT were included in
the model if the rates were statistically signiﬁcantly different
in the ivabradine and background therapy cohorts (Table S4).
Asymptomatic bradycardia, symptomatic bradycardia, atrial
ﬁbrillation, blurred vision, and phosphenes met the inclusion
criteria. The data were reanalyzed to provide the number of
events, rather than the number of patients experiencing an
AE. Risk of an AE was assumed to remain constant across the
time horizon.
Cost inputs
Drug acquisition costs. The US wholesale acquisition cost
for ivabradine as of April 15, 2015, was $375 per month or
$4500 per year (assuming 100% compliance). The same cost
was applied to both the 5-mg and the 7.5-mg dose in the
model.
Hospitalization. Using US claims data, HF-related, non-HF
cardiovascular–related, and non-cardiovascular–related hos-
pitalizations were assigned per-event costs (Table S5). In the
model, AEs were assumed to be managed through physician
HF 0, 
CV 0
HF 0, 
CV 1
HF 1, 
CV 1
HF 0, 
CV 2
HF 1, 
CV 2
HF 2, 
CV 2
HF 0, 
CV ≥ 3
HF 1, 
CV ≥ 3
HF 2, 
CV ≥ 3
HF ≥ 3, 
CV ≥ 3
HF Hospitalization
Non-HF CV hospitalization
0.736
0.716 0.660
0.683 0.640 0.662
0.6030.607 0.6420.664
Figure 1. State transition diagram. CV indicates cardiovascular; HF, heart failure. The number listed at
the bottom of each hospitalization state box indicates the patient utility value derived from the base-case
utility regression equation.
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visits or emergency department visits (Table S5). The unit
costs of AE management for commercially insured patients
were sourced from the Physicians’ Fee and Coding Guide13
and the costs for Medicare Advantage patients were sourced
from the Department of Health and Human Services Centers
for Medicare & Medicaid Services Medicare physician fee
schedule look-up tool and the hospital outpatient prospective
payment system ﬁles (July 2014).14
Quality-of-life inputs
Data from SHIFT were used to inform the model utility inputs
at different hospitalization states. Two regression equations
were developed to estimate change from baseline in the
EuroQoL 5 dimensions (EQ-5D) index score, using 3 main
independent variables including treatment, b-blocker use, and
number of hospitalizations. The number of hospitalizations
was included as either a categorical variable (1 versus 0, 2
versus 0, and ≥3 versus 0) or a dichotomous variable (yes
versus no) to derive the explicit equation or minimal equation,
respectively (Table S6). For the base case, the explicit
equation was used where the utility reduction was capped
after 3 hospitalizations. Figure 1 depicts the hospitalization
state utilities derived from the base-case regression equation.
The minimal equation was used as a sensitivity analysis.
Sensitivity analysis inputs
One-way sensitivity analysis was conducted to explore the
impact of model inputs and assumptions on the results. The
parameters varied in the sensitivity analysis; they included
the time horizon, cost of ivabradine, data source used for
event rates, utility regression equations, disutility of AEs, b-
blocker use, and costs associated with AEs. A probabilistic
sensitivity analysis was conducted to evaluate the impact of
varying cost, utility, hospitalization rate, and treatment hazard
ratio parameters simultaneously on the results.
Statistical Analysis
To derive clinical and quality-of-life inputs for the model, a
post hoc analysis of SHIFT data was conducted. The
randomized set was used. Mortality and ﬁrst hospitalization
rates for each type (HF and non-HF cardiovascular) in each
treatment group were calculated using the randomized set by
dividing the number of ﬁrst events for each patient by the
total number of patient-years (ie, the number of patient-years
from randomization until occurrence of the event or end of
follow-up, whichever came ﬁrst). Rates of treatment-emergent
AEs were calculated using the safety set as the total number
of emergent AEs divided by the number of patient-years at
risk (from ﬁrst to last study drug intake+2 days) in accor-
dance with the clinical study report.
Hazard ratios and 95% CIs for time to death due to an HF
or a non-HF cardiovascular reason, as well as time to HF or
non-HF cardiovascular hospitalization in the ivabradine group
versus the placebo group were estimated from Cox propor-
tional-hazards models with adjustment for b-blocker intake at
baseline for concordance with prior publications.9
A predictive equation for change from baseline in EQ-5D
was derived using a generalized linear mixed model, which
included treatment, baseline EQ-5D score, baseline b-blocker
use, and time-dependent variables for HF and non-HF
cardiovascular hospitalizations. Raw EQ-5D scores were
converted to utilities using UK tariffs. For this analysis,
patients with a nonmissing baseline value and at least 1
nonmissing postbaseline value for the EQ-5D index from the
patient-reported outcomes (PRO)–SHIFT substudy were used.
All analyses were performed using SAS version 9.4 (SAS
Institute Inc, Cary, NC).
Results
Base-Case Results, Commercial Perspective
Overall, the results of the base-case analysis indicated that
ivabradine+background therapy was dominant over back-
ground therapy alone, with lower cost and better health
outcomes (Table 1). The total costs, including hospitalization,
AE, and drug acquisition costs, were estimated to be
$369 762 with the addition of ivabradine, compared with
$378 356 for background therapy alone over a 10-year time
horizon. Therefore, ivabradine as an add-on treatment
resulted in an estimated incremental savings of $8594. This
reduction in cost occurred despite the additional $27 201 in
drug acquisition costs and the additional $2572 in AE costs,
because of the substantial reduction in costs associated with
hospitalization. This included an incremental saving of
$31 295, $34 112, and $38 366 in HF-related, cardiovascu-
lar-related, and all-cause hospitalization costs, respectively
(Table 1). Life years (LYs) and quality-adjusted life years
(QALYs) were also increased with the addition of ivabradine,
with an incremental improvement of 0.21 and 0.24 for LYs
and QALYs, respectively (Table 1).
Base-Case Results, Medicare Advantage
Perspective
The base-case results for the Medicare Advantage population
showed that ivabradine+background therapy was cost-
effective compared to background therapy alone. The total
costs, including hospitalization, AE, and drug acquisition
costs, were estimated to be $227 125 with the addition of
ivabradine, compared with $222 212 for background therapy
alone over a 10-year time horizon. The increase in drug
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acquisition and AE costs ($24 512 and $1256, respectively)
was largely offset by the reduction in hospitalization cost
($20 855), leading to a modest cost increase of $4913 over
10 years. A similar health beneﬁt was predicted in the
Medicare Advantage population as in the commercial popu-
lation, with an incremental gain of 0.16 LYs and 0.20 QALYs
(Table 1). The ICER in the Medicare Advantage population was
$24 920/QALY.
Sensitivity Analysis
Results of the 1-way sensitivity analysis are presented in
Table 2 and Figure 2. The strongest drivers of the model were
time horizon and treatment effect on HF hospitalization and
mortality. Ivabradine was conﬁrmed to be cost-effective in all
scenarios listed in Table 2 (ICER ≤$50 000/QALY). The
results were relatively insensitive to changes in other
assumptions such as drug price, treatment effect on non-HF
cardiovascular hospitalizations and noncardiovascular hospi-
talizations, background therapy hospitalization rates and
mortality rates, and AE disutility (Figure 2).
Probabilistic Sensitivity Analysis
A probabilistic sensitivity analysis was run for 1000 replica-
tions with appropriate distributions assigned to each selected
parameter based on the conﬁdence bounds and standard
errors provided in Tables S1 through S6 (cost: Gamma
distribution, utility: Normal distribution, hospitalization rates
and treatments: Normal distribution). The resulting cost-
effectiveness plane and acceptability curve (Figures 3 and 4)
showed that ivabradine was likely to be cost-effective relative
to background therapy for all willingness-to-pay thresholds
(60% likely at $0 per QALY gained threshold; 85% for
$150 000 per QALY gained).
Discussion
The base-case analysis indicated that the drug costs associ-
ated with adding ivabradine to background therapy would be
largely offset by the cost savings associated with reduced
hospitalization. Overall, the addition of ivabradine resulted in
total cost savings for the commercial population and a
modest cost increase in the Medicare Advantage population,
and higher LYs and QALYs compared with background therapy
in both populations. The lower cost of hospitalization coupled
with a high disease prevalence led to the modest cost
increase in the Medicare Advantage population. The ﬁrst
factor reduces the economic offset caused by ivabradine, and
the second results in a higher number of patients, leading to
higher drug costs. An American College of Cardiology/
American Heart Association Task Force recently published a
statement on cost methodology where they proposed differ-
ent categories of value.10 The highest category is the category
of “high value,” which is deﬁned as a therapy that provides
either better outcomes at a lower cost or an ICER of <
$50 000 per QALY gained. Therefore, in the base case and in
all of the sensitivity analyses, ivabradine would be considered
“high value” based on the American College of Cardiology/
American Heart Association value guidelines.10
These results are consistent with those of several inter-
national studies investigating the cost-effectiveness of adding
ivabradine to background therapy for HF. In a study
conducted in the United Kingdom, the additional £3341
associated with ivabradine drug therapy and follow-up costs
was partially offset by a reduction in hospitalization costs of
Table 1. Base-Case Model Results
Commercial Medicare Advantage
Ivabradine Background Therapy Incremental Ivabradine Background Therapy Incremental
Hospitalization costs
HF $254 960 $286 255 $31 295 $143 394 $159 515 $16 121
Cardiovascular $287 802 $321 915 $34 112 $165 010 $182 681 $17 672
All cause $337 268 $375 634 $38 366 $200 032 $220 887 $20 855
AE costs $5294 $2722 $2571 $2581 $1325 $1256
Drug costs $27 201 NA $27 201 $24 512 NA $24 512
Total costs $369 762 $378 356 $8594 $227 125 $222 212 $4913
Health outcomes
LYs 6.04 5.83 0.21 5.45 5.28 0.16
QALYs 4.02 3.78 0.24 3.60 3.40 0.20
AE indicates adverse event; HF, heart failure; LYs, life years; NA, not applicable; QALY, quality-adjusted life year.
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£965.15 The ICER per QALY was estimated to be £8498 for
patients with a HR ≥75 bpm, which is substantially lower than
the £20 000 to £30 000 per QALY threshold used to
determine cost-effectiveness in the United Kingdom.15 Similar
results were identiﬁed in a study conducted in Greece, in
which the ICER per QALY with the addition of ivabradine to
background therapy was estimated at €9986, well below the
cost-effectiveness threshold of €36 000 per QALY.16
A budget-impact model has also demonstrated potential cost
offsets associated with the use of ivabradine in both a
commercial and a Medicare Advantage population from a US
payer perspective (Jeffrey S. Borer, MD, Anuraag R. Kansal,
PhD, Emily D. Dorman, MPH, MBA, Stanimira Krotneva, MSc,
Ying Zheng, MHSA, MS, Harshali K. Patel, MS, PhD, Luigi
Tavazzi, Michel Komajda, Ian Ford, Michael Böhm, Adrian
Kielhorn, in press, Journal of Managed Care & Specialty
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Figure 2. Tornado diagrams on (A) incremental cost and (B) incremental QALYs comparing the relative
importance of model parameters for ivabradine vs background therapy. CV indicates cardiovascular; HF,
heart failure; QALY, quality-adjusted life year.
Table 2. Results of Sensitivity Analysis
Parameters Base-Case Inputs Sensitivity Analysis Inputs ICER (US$)
Base case (commercial,
US claims data)
NA NA Cost saving
Treatment effect only on
first HF hospitalization
SHIFT analysis Hazard ratio=1 for all hospitalizations
other than first HF event
$48 571
Treatment effect on first
HF hospitalization
SHIFT analysis 95% CI-lower bound
95% CI-upper bound
Cost saving
$16 185
Treatment effect on mortality SHIFT analysis 95% CI-lower bound
95% CI-upper bound
$21 907
Cost saving
Time horizon 10 years Lifetime
5 years
$30 082
Cost saving
Hospitalization rates US claims SHIFT $11 574
HF indicates heart failure; ICER, incremental cost-effectiveness ratio; NA, not applicable; SHIFT, Systolic Heart failure treatment with the If inhibitor ivabradine Trial.
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Pharmacy). In the current study, cost offsets were only
observed in a commercial population, whereas the Medicare
Advantage population had a modest cost increase. This can
be attributed to a number of differences between the 2
models. A key factor contributing to differences across the
results in the models is how mortality was treated. In our
cost-effectiveness model, the effect of ivabradine on mortality
was incorporated. This results in patients on ivabradine living
longer, thus incurring more cost. However, for the budget-
impact model, mortality was considered at the natural rate
and no mortality beneﬁt due to ivabradine was incorporated.
In our cost-effectiveness model, therefore, ivabradine was
found to be a dominant treatment over background therapy in
the US commercially insured population, with a net cost
saving. This is because higher cost offsets from reduced
hospitalizations were realized, which can be largely attributed
to a higher cost per hospitalization in the United States than
in the United Kingdom or elsewhere in the European Union.17
This model has a number of strengths. First, the US claims
data were derived from real-world utilization of healthcare
resources, which was used to inform the reference hospital-
ization rates and costs. The noncardiovascular mortality rates
were taken from the US life table, and were therefore speciﬁc
to the US population. The model also had the ﬂexibility to use
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Figure 4. Cost-effectiveness acceptability curve. QALY indicates quality-adjusted life year.
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Figure 3. Cost-effectiveness plane: ivabradine vs SoC. QALY indicates quality-adjusted life year; SoC,
standard of care.
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hospitalization rates from SHIFT. This allowed for all hospi-
talization, mortality, and treatment effect parameters to be
informed by a consistent source.
The model does have several limitations. First, the
background therapy hospitalization rates and costs derived
from US claims data were based on the general chronic HF
population. It was not feasible to further reﬁne the population
to match the exact eligible population for ivabradine,9 as
clinical parameters such as HR and New York Heart Associ-
ation classes were not collected in the claims database.
Second, as the real-world effectiveness of ivabradine in the
United States is to be studied, the model extrapolates
the efﬁcacy outcome from the clinical trial (SHIFT study) to
the real-world setting. Third, efﬁcacy inputs based on the
SHIFT study do not differ between the commercial (age
18–64 years) and Medicare Advantage populations. Although
the cost and background frequency of hospitalizations varied
between the 2 groups of patients, we applied the same clinical
beneﬁt to both populations. Finally, the model does not
include costs of background therapy; therefore, the reference
case does not represent the total costs of background
therapy. The model also assumed that during AE visits, the
same level of care was provided to patients, regardless of
treatment arm. It is expected that these cost components
would have minimal impact on the model outcome as the cost
outcomes were predominantly driven by hospitalization and
drug costs.
In summary, the results of this cost-effectiveness model
suggest that ivabradine+background therapy for HF would be
cost-effective from a US payer perspective and would be
considered “high value” based on American College of
Cardiology/American Heart Association value guidelines.
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SUPPLEMENTAL MATERIAL 
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Table S1. Annual Hospitalization Rates From US Claims
Parameter (Type/Number of 
Hospitalization[s])
Commercial 
Reference Rate
(95% CI)
(Base Case)
Medicare 
Advantage 
Reference Rate
First HF for patients with no non-HF CV 0.54 (0.50-0.59) 0.66
First HF for patients with 1+ non-HF CV 0.91 (0.75-1.09) 1.13
2 HF 2.01 (1.67-2.39) 2.01
3 HF 2.01 (1.67-2.39) 2.01
≥ 3 HF 2.01 (1.67-2.39) 2.01
Non-HF CV for patients with 0 CV 0.05 (0.04-0.05) 0.06
Non-HF CV for patients with 1 CV 0.14 (0.13-0.16) 0.19
Non-HF CV for patients with 2 CV 0.19 (0.16-0.22) 0.25
Non-HF CV for patients with ≥ 3 CV 0.28 (0.23-0.34) 0.38
Non-CV 0.52 (0.50-0.54) 0.65
Source: US claims hospitalization rates analysis scaled based on SHIFT hospitalization 
rates. Analysis of SHIFT trial data showed that patients are subject to higher risk of HF 
hospitalization as they experience more HF hospitalizations, and are subject to higher risk of 
non-HF CV hospitalization as they experience more CV hospitalizations. The US claims data 
analysis only estimated the cumulative (1, 2, and ≥ 3) hospitalization rate for HF and non-HF 
CV hospitalizations. To derive the hospitalization rate specifically for 1, 2, and ≥ 3 
hospitalizations based on the cumulative rate from US claims data, the corresponding 
cumulative rates were estimated in SHIFT and then used to estimate a scaling factor (US 
claims data rate/SHIFT rate) between the hospitalization rate from US claims data and 
SHIFT. This scaling factor was then applied to the event rates in Supplemental Table 2 to 
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derive the hospitalization rate for 1, 2, and ≥ 3 hospitalizations for US claims data. To 
minimize the risk of overestimating hospitalization rates using US claims data, the rate was 
capped at the highest rate reported in SHIFT (2.01). 
CI indicates confidence interval; CV, cardiovascular; HF, heart failure; and SHIFT, Systolic 
Heart failure treatment with the If inhibitor ivabradine Trial. 
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Table S2. Annual Hospitalization Rates and Treatment Effect on Hospitalization 
From SHIFT 
Parameter (Type/Number of 
Hospitalization[s])
Hospitalization
Rate
(Reference Case)
Hazard Ratio 
(95% CI)
Ivabradine vs Placebo
First HF for patients with no non-HF CV 0.12 0.73 (0.64-0.82)
First HF for patients with 1+ non-HF CV 0.20 0.84 (0.63-1.11)
2 HF 0.66 0.84 (0.70-1.01)
3 HF 0.99 1.09 (0.83-1.42)
≥ 3 HF 2.01 0.94 (0.73-1.21)
Non-HF CV for patients with 0 CV 0.12 0.97 (0.86-1.09)
Non-HF CV for patients with 1 CV 0.37 0.99 (0.83-1.18)
Non-HF CV for patients with 2 CV 0.48 1.08 (0.83-1.39)
Non-HF CV for patients with ≥ 3 CV 0.72 0.96 (0.74-1.24)
Non-CV 0.14 0.89 (0.80-0.98)
Source: SHIFT data analysis. 
CI indicates confidence interval; CV, cardiovascular; HF, heart failure; and SHIFT,
Systolic Heart failure treatment with the If inhibitor ivabradine Trial. 
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Table S3. Annual Mortality Rates and Hazard Ratios Derived From SHIFT Data 
Parameter Annual Incidence Rate 
for Background Therapy
(95% CI)
Hazard Ratio
(95% CI)
Ivabradine vs Placebo
HF mortality 0.026 (0.022-0.030) 0.74 (0.58-0.94)
Non-HF CV
mortality
0.057 (0.052-0.064) 0.98 (0.84-1.14)
Non-CV mortality Informed by US life table 
adjusted to exclude CV-related 
deaths
Source: SHIFT data analysis. 
CI indicates confidence interval; CV, cardiovascular; HF, heart failure; and SHIFT,
Systolic Heart failure treatment with the If inhibitor ivabradine Trial. 
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Table S4. AE Rates per Year
Type of AE Annual Event Rate, 
Placebo, %
Annual Event Rate,
Ivabradine, %
Asymptomatic bradycardia 0.8 3.6
Symptomatic bradycardia 0.6 2.9
Atrial fibrillation 4.6 5.8
Blurred vision 0.1 0.4
Phosphenes 0.3 1.8
Source: SHIFT data analysis.
AE indicates adverse event; and SHIFT, Systolic Heart failure treatment with the If
inhibitor ivabradine Trial. 
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Table S5. Hospitalization and AE Costs
Cost per Event
Commercial, $
Cost per Event
Medicare 
Advantage, $
Reference/Resource Used
Type of hospitalization (survive or die)
First HF 39,779 24,746 US claims data
Second HF 31,171 19,899 US claims data
≥ Third HF 32,422 18,684 US claims data
First non-HF CV 29,082 18,596 US claims data
Second non-HF CV 27,684 16,082 US claims data
Third+ non-HF CV 30,915 15,610 US claims data
Non-CV related 17,904 11,489 US claims data
Type of AE
Asymptomatic 
bradycardia
142 73 Physician visit for cardiac 
issue of “moderate 
severity”1,2
Symptomatic 
bradycardia
686 367 Physician visit for cardiac 
issue of “moderate severity”
or ED visit for cardiac issue 
of “high severity”1,2
Atrial fibrillation 686 367 Physician visit for cardiac 
issue of “moderate severity”
or ED visit for cardiac issue 
of “high severity”1,2
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Blurred vision 187 126 Physician visit for 
comprehensive 
ophthalmological services1,2
Phosphenes 187 126 Physician visit for 
comprehensive 
ophthalmological services1,2
AE indicates adverse event; CV, cardiovascular; ED, emergency department; and 
HF, heart failure. 
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Table S6. Utility Regression Equations
Independent Variable Parameter Estimates
Explicit No. of 
Hospitalizations
(SE)
(Base Case)
Minimum No. of 
Hospitalizations
(SE)
Intercept 0.425 (0.008) 0.425 (0.008)
Treatment 0.009 (0.005) 0.009 (0.005)
Beta-blocker use (no vs yes) at 
baseline
−0.011 (0.008) −0.011 (0.008)
Baseline EQ-5D index score −0.540 (0.010) −0.540 (0.010)
≥ 1 HF hospitalization −0.084 (0.006)
≥ 1 non-HF CV hospitalization −0.032 (0.005)
1 HF hospitalization −0.076 (0.007)
2 HF hospitalizations −0.074 (0.013)
≥ 3 HF hospitalizations −0.133 (0.016)
1 non-HF CV hospitalization −0.020 (0.006)
2 non-HF CV hospitalizations −0.053 (0.011)
3 non-HF CV hospitalizations −0.072 (0.015)
Source: PRO-SHIFT study data analysis (Amgen Data on File, 2014)  
CV indicates cardiovascular; EQ-5D, EuroQol-5D; HF, heart failure; SE, standard 
error; and SHIFT, Systolic Heart failure treatment with the If inhibitor ivabradine Trial. 
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